The rate of 5-year overall survival in patients with myelodysplastic syndrome who underwent second allogeneic hematopoietic stem cell transplantation was 25.3%.
The increased risk for infection seen in pediatric patients receiving transplants from unrelated donors could be a result of intensified graft-versus-host disease prophylaxis.
Patients demonstrated a 5-year overall survival rate of 86%, with all but 2 patients achieving neutrophil engraftment.
Rates of leukemia-free and overall survival were 20% and 30%, respectively, at 2 years and 12% and 14%, respectively, at 5 years.
Impaired ability to conduct instrumental activities of daily living and high disease risk index were associated with poorer outcomes.
No association was found between number of organs involved and progression-free or overall survival in patients with amyloidosis who underwent transplant.
Busulfan plus melphalan may be a viable pretreatment conditioning regimen for patients undergoing autologous hematopoietic stem cell transplantation.
Patients who developed cerebrovascular disease following allogeneic hematopoietic stem cell transplantation experienced decreased survival.
Proteasome inhibitors and immunomodulatory drugs have demonstrated improvements in survival and response in patients with multiple myeloma.
Though adoptive T-cell transfer has demonstrated clinical applicability, many barriers prevent it from becoming a standard of care following transplant.
